{"id":"W4413840903","doi":"10.1016/s0140-6736(25)01665-4","title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"MSD Sharp and Dohme; National Heart, Lung, and Blood Institute; Relypsa; National Medical Research Council; Respicardia; MSD K.K.; Abbott Vascular; National Institutes of Health; Bristol-Myers Squibb; Akebia Therapeutics; Sanofi; Abiomed; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Servier; Pfizer; Moderna; Novo Nordisk; Medical Research Council; Verily Life Sciences; Boston Scientific Corporation; Eli Lilly and Company; AstraZeneca; Amgen; Vifor Pharma; Ministero della Salute; Duke Clinical Research Institute; Cytokinetics; Pharmaceuticals Bayer; American Regent; American Heart Association","keywords":"Ejection fraction; Placebo; Heart failure; Medicine; Internal medicine; Double blind; Cardiology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639423,0.00175929,0.004261782,0.0004165548,0.0005010155,0.001251279,0.001074304,0.002632996,0.0109162],"category_scores_gemma":[0.001732706,0.0006493553,0.002458469,0.0004369898,0.001209047,0.001190794,0.0005200224,0.003187872,0.001340693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006997158,"about_ca_system_score_gemma":0.0009054616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001634818,"about_ca_topic_score_gemma":0.003733655,"domain_scores_codex":[0.9994752,0.0002316191,0.00003173798,0.0001105639,0.00004205349,0.0001089271],"domain_scores_gemma":[0.9993955,0.0001971846,0.0001393647,0.00004625207,0.00003439818,0.0001872387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9853822,0.001235667,0.0003091679,0.001149432,0.001209008,0.00003334768,0.0000344377,0.0001379318,0.001397879,0.0001478361,0.001065242,0.007897802],"study_design_scores_gemma":[0.9892219,0.009233452,0.0007279342,0.00003392702,0.000287266,0.00001368487,0.00001216515,0.00007845294,0.00006276714,0.00007804252,0.0002424706,0.000007946478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9528685,0.02803626,0.001415401,0.002643044,0.002417062,0.004108663,0.002736514,0.0004936949,0.005280837],"genre_scores_gemma":[0.9734447,0.00905762,0.001874556,0.003498907,0.001087481,0.003682396,0.001784553,0.00005995714,0.005509869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0109162,"threshold_uncertainty_score":0.03651834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01874099483974678,"score_gpt":0.3017724271595295,"score_spread":0.2830314323197827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}